Safety investigation of Fexuprazan, a gastric acid secretion inhibitor, in patients with cirrhosis

Soonchunhyang University Medical Center0 个研究点目标入组 99 人开始时间: 待定最近更新: 2024年3月4日

试验速览

暂无简介。

•Test group: ? Liver cirrhosis patients between 20 and 75 years old
•?Milan gastroesophageal reflux requiring endoscopic drug treatment within the last 6 months
•Patients with liver cirrhosis who have been diagnosed with the disease
•Control group: ? Patients with no evidence of disease between the ages of 20 and 75
•?Patients with no evidence of liver disease in blood tests or imaging tests
•? Milan gastroesophageal reflux disease was diagnosed by endoscopy within the last 6 months.
•Patients who took P-CAB

•1. Patients with non-targeted liver cirrhosis who have variceal hemorrhage, hepatic encephalopathy, Gansin syndrome, or spontaneous peritonitis
•2. Patients who have experienced side effects after previously using Proton Pump Inhibitor
•3.Patients with untreated malignant tumor
•4. Pregnant patients
•5. Patients who did not consent to participate in the study
•6. If you have taken fexuprazan at least 6 months prior to the time of Inclusion

发起方

Soonchunhyang University Medical Center